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Abstract 
The effects of various fat subtypes can have a profound influence on our health and performance, not 
only in the early years of life but also as we age. The long-chain omega-3s docosahexaenoic and 
eicosapentaenoic acid appear to have a positive role in our mental and physical health. 
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The past century has seen significant changes in Western
diets. Intake of saturated fatty acids and omega-6 polyun-
saturated fatty acids (PUFAs) has increased, with a con-
comitant lowering of omega-3 PUFAs intakes, particularly
the long-chain omega-3 PUFAs docosahexaenoic acid (DHA)
and eicosapentaenoic acid (EPA) (Fig. 1). 
The importance of DHA and EPA in the development of
important tissues such as the brain in early life has been
acknowledged for many years. The inclusion of fish oil with a
high DHA : EPA ratio in infant formula is common throughout
the world because it resembles the fatty acid profile of
human breast milk. More recently research into healthy
ageing has shown that DHA and EPA may have health
benefits in the areas of cardiovascular health, rheumatoid
arthritis and other inflammatory conditions, cognitive and
memory function, eye health, mental disorders such as
depression, and in obesity and weight control.
Figure 1. Chemical structures of docosahexaenoic acid (DHA), eicosapen-
taenoic acid (EPA) and docosapentaenoic acid (DPA).
Omega-3 structure and function
DHA and EPA can reverse omega-3 deficiency. The position of
the double bonds within their hydrocarbon chain gives
omega-3 PUFAs their name and their physical and physio-
logical properties. For example, in omega-3s the terminal
double bond (i.e. closest to the methyl end of the hydro-
carbon chain) is on C3. In omega-6 PUFAs the terminal
double bond is on C6. The omega-6 and omega-3 families of
PUFAs have a range of members, including linoleic acid and
α-linolenic acid (Fig. 2), both of which are plant-derived fatty
acids. Although animals cannot produce these fatty acids,
mammals have a requirement for them, and thus they are
regarded as essential. 
Mammalian cells cannot synthesise these fatty acids, but
they can metabolise them by further saturation and elon-
gation. Further metabolism of EPA to DHA is mediated by the
formation of docosapentaenoic acid (DPA; see Fig. 1), then
the addition of two carbons and desaturation at the Δ6
position and finally β-oxidation to yield DHA.1 It is important
to note that recent studies have revealed that the conversion
of α-linolenic acid into its longer chain derivatives is not
efficient in humans, and estimates for the conversion of α-
linolenic acid into EPA from stable isotope studies have
varied between 0.2% and 8%.2 The role of these fatty acids in
the body, established through extensive nutritional and
clinical research, is critical for human health and per-
formance, although there appear to be significant dif-
ferences in their physiological effects. 
Figure 2. Chemical structures of linoleic acid and α-linolenic acid.
Heart health
The long-chain PUFAs DHA and EPA are thought to decrease
the risk of coronary heart disease by several mechanisms.
Animal and clinical studies have shown that they decrease
triglycerides, inhibit inflammatory processes, increase high-
density lipoproteins, improve heart rate variability, decrease
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risk of thrombosis, slow progression of atherosclerotic
plaques and reduce blood pressure, among other things. 
It is the area of secondary prevention of heart disease that
provides exciting evidence of the physiological effects of fish
oils rich in DHA and EPA. The clinical effectiveness of fish oil
was most strikingly demonstrated in an Italian secondary
prevention study in 2002.3 In this study, Marchioli and col-
leagues randomised 11 323 survivors of myocardial
infarction to omega-3 supplements (885 mg of EPA +
DHA/day), vitamin E (300 mg/day), both or neither (control).
After 12 months, compared to the control group, the
researchers demonstrated a reduction of cardiovascular
deaths by 30% and a reduction of sudden death by 45% in
the fish oil group, but not in the other groups. These findings
were further supported earlier this year with release of
results of the five-year heart failure study by the same group.
Although this showed a moderate benefit (risk reduction for
all-cause mortality was 1.8%) that was smaller than
expected, the authors noted that it was obtained in a popu-
lation already treated with recommended therapies and was
consistent across all the predefined subgroups.4
The National Heart Foundation of Australia has long
promoted the increased intake of long-chain omega-3s to
improve cardiovascular health. Acknowledging the large
body of evidence supporting regular consumption of DHA
and EPA to improve heart health the foundation released a
position paper5 recommending the following long-chain
omega-3 consumption levels: 
• 500 mg per day of DHA and EPA to lower risk of coronary
heart disease in Australian adults. This can be obtained
from a combination of two to three serves of oily fish per
week, fish oil capsules or liquid, and food and drinks
enriched with long-chain omega-3s
• 1000 mg per day of DHA and EPA for people with estab-
lished coronary heart disease.
Anti-inflammatory properties
Early last year Goldberg and Katz published a meta-analysis
on 17 randomised controlled trials assessing the effec-
tiveness of omega-3s at alleviating rheumatoid arthritis and
associated joint pain. The authors concluded that long-chain
omega-3 PUFAs (> 2.7 g/day) are an attractive adjunctive
treatment for joint pain associated with rheumatoid arthritis
and other inflammatory diseases.6 The ability of the omega-
3 rich fish oils to suppress synthesis of inflammatory
cytokines through competition with arachidonic acid for pro-
duction of inflammatory eicosanoids appears to be funda-
mental to their action. Whether the ability to reduce pain is
due to the suppression of the inflammation underlying
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inflammatory disease or direct effects on prostaglandins or
possibly cytokines in the spinal cord dorsal horn remain to be
fully elucidated.
Preventing cognitive decline and depression
Adequate dietary availability of DHA and EPA is fundamental
to brain function. DHA is the most important long-chain
omega-3 PUFA for brain growth and development and the
retention of cognitive and memory functions. Its importance
in relation to reducing the effects of ageing on cognitive per-
formance is now the subject of active research.
Epidemiological studies indicate relatively high DHA and EPA
intake is linked to lower relative risk of dementia incidence
or progression.7 In this longitudinal cohort study, 5386 par-
ticipants aged 55 found that fish consumption was inversely
related to dementia incidence, and more specifically to the
risk of developing Alzheimer’s disease. This was contrasted
with a smaller study that found no association.8 However,
data from the latter study later confirmed an inverse linear
relationship between DHA/EPA levels and cognitive decline.9
Seven double-blind randomised controlled trials of omega-3
fatty acids have been conducted for depression.10 Of these,
six studies reported clinically significant benefits of long-
chain omega-3s in reducing the effects of depression.
However, it remains unclear whether omega-3 supplemen-
tation is effective independent of antidepressant treatment
for depressed patients in general or only those with
abnormally low concentrations of these PUFAs. DHA is the
most common fatty acid in the brain and the full range of
actions within the brain is yet to be determined.
Role in obesity and weight control
A positive energy balance (energy intake > energy expen-
diture), in which total fat intake plays an important role, is
commonly regarded as a major factor contributing to obesity.
New evidence is emerging showing the positive role that DHA
and EPA have on appetite control. In a study published in
Appetite, 112 subjects were provided with either low or high
long-chain omega-3s for a period of two months. The authors
concluded that long-chain omega-3 PUFA intake modulates
postprandial satiety in overweight and obese volunteers
during weight loss.11 PUFAs are a major component of
synaptic endings, are closely involved in the transport of
appetite-regulating molecules such as dopamine and are
related to receptor affinity. 
Improving dietary intakes of long-chain
omega-3s
A good dietary source of long-chain omega-3 PUFAs is fish
such as salmon, tuna, herring and mackerel. Essentially all
fish oil is high in long-chain omega-3 PUFAs, although the
proportions of DHA, DPA and EPA can vary. Presently, people
in most Western countries have diets with relatively low
levels of fish. The consumption of omega-3 PUFAs, in par-
ticular DHA and EPA, has been shown to be suboptimal for all
sections of the Australian population. It has been reported
that ‘the average omega-3 intake by Australians has been
estimated at 246 mg/day comprising 75, 71 and 100 mg/day
from EPA, DPA and DHA respectively’.12 Compare this to the
suggested intake of at least 500 mg per day promoted by
most health authorities for cardiovascular health. Despite
the body of evidence suggesting the importance of long-
chain omega-3 PUFAs, dietary goals are difficult to achieve
through the consumption of fish alone.13 The National Heart
Foundation of Australia also notes that people who do not
consume enough long-chain omega-3 PUFAs from fish
should use supplements and enriched foods. With
advancements in microencapsulation technologies omega-3
PUFAs are now available in a wide range of food and bev-
erages.
Long-chain omega-3 PUFAs are fundamentally important to
healthy ageing as demonstrated by their health-promoting
abilities across the wide range of age-related health
problems. With the emergence of a wider variety of both food
products enriched with marine oils and omega-3 sup-
plements, which add to omega-3 intakes from fish, the
potential to improve health and the quality of life throughout
the ageing process is encouraging. 
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